ORIENT-15
01 Dec 2020
ORIENT-15
NCT03748134
A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)
Innovent Biologics (Suzhou) Co. Ltd.
Cancer Type | Stomach & Oesophageal |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years to 75 years |
Sex | Both |
Tumour Stream | Esophageal squamous cell carcinoma |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2018-12-13 |
Anticipated End Date | 2022-07-30 |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
pamela.cooper@sa.gov.au | |
Phone | 08 8222 6140 |
Principal Investigator | Professor Tim Price |
Recruitment Status | Not Yet Recruiting |